SynDevRx, Inc.

2:30 PM - 2:45 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
SynDevRx is a clinical-stage biotech company developing drug candidates to treat cancers driven by metabolic hormones. Our first application is in combination with the PI3Ka inhibitor alpelisib in breast cancer, where we solve a major issue (hyperglycemia) and have demonstrated synergy with the drug class on efficacy.
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
SDX-7320
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1